top of page

Clinical Trials

Abstract Paint

Clinical Trials - Actively Recruiting

Rheumatoid Arthritis/Artritis Reumatoide

  • Eli Lilly- J1A-MC-KDAF A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate
    Peresolimab in Adult Participants with Moderately-to-Severely Active Rheumatoid Arthritis


  • Eli lilly-J1V-MC-IMMA A Master Protocol for a Randomized, Placebo-Controlled
    Clinical Trial of Multiple Interventions for the Treatment of Systemic

Lupus Erythematosus

  • AbbVie -Protocol for M23-699 SELECT-SLE: A Phase 3 Program to Evaluate the Safety and
    Efficacy of Upadacitinib in Subjects with Moderately to Severely Active SLE


  • Eli Lilly-I5T-MC-AACM A Study of Donanemab Versus Placebo in Participants at Risk for
    Cognitive and Functional Decline of Alzheimer's Disease


  • Eli Lilly- J2A-MC-GZGS A Phase 3, Open-Label Study of Once Daily LY3502970 Compared
    with Insulin Glargine in Adult Participants with Type 2 Diabetes and Obesity or Overweight at
    Increased Cardiovascular Risk (ACHIEVE-4)


Artritis Psoriatica / Psoriatic Arthritis


  • Janssen: Protocol CNTO1959PSA3005; Phase 3b A Phase 3B, Multicenter, Randomized,
    Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab
    Administered Subcutaneously in Participants with Active Psoriatic Arthritis who had an
    Inadequate Response and/or Intolerance to One Prior Anti-Tumor Necrosis Factor α Agent


Clinical trials are part of clinical research and are at the heart of all medical advances. Clinical trials look at new ways to prevent, detect, or treat diseases. Treatments might include new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses.

People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to possibly receive the newest treatment and to have additional care and attention from the clinical trial staff. Clinical trials offer hope for many people and an opportunity to help researchers find better treatments for others in the future.

Clinical Trials - Ongoing (Not recruiting)


Rheumatoid Arthritis/Artritis Reumatoide

  • Eli Lilly- Protocol I4V-MC-JAJA(d) (RA-BRIDGE) A Randomized, Active-Controlled, Parallel-
    Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis

  • Protocol M20-466 Moderate to Severe Rheumatoid Arthritis: A Phase 2b, Dose-Ranging, Safety
    and Efficacy Study of ABBV-154700

Lupus Erythematosus

  • Abbvie- Protocol M20-186 Systemic Lupus Erythematosus: A Phase 2, Long-Term Extension
    (LTE) Study in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus

  • Eli Lilly - Protocol J1P-MC-KFAJ(1.1)One-on-One Participant Interviews to Evaluate the
    Content Validity and Interpretation of Select Patient-Reported Outcomes Instruments A
    Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in
    Adults with Systemic Lupus Erythematosus

Artritis Psoriatica / Psoriatic Arthritis


  • Abbvie- Protocol M16-011 Psoriatic Arthritis: Risankizumab Therapy Vs Placebo in csDMARD-
    IR Subjects


  • Emerald- Protocol EHP-101-SS01 Protocol Title: A Phase IIa, Double-Blind, Randomised,
    Intracohort Placebo-Controlled, Multicentre Study to Evaluate the Safety, Tolerability and
    Preliminary Efficacy of EHP-101 in Patients with Diffuse Cutaneous Systemic Sclerosis


  • Abbvie- Protocol M14-430 A Multicenter, Randomized, Double-Blind, Placebo-Controlled
    Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-
    494) in Subjects with Crohn's Disease Who Completed the Studies M14-431 or M14-433

  • Abbvie- Protocol M20-371 Moderate to Severe Crohn's Disease: A Phase 2 Safety and Efficacy
    Study of ABBV-154

bottom of page